| Revision as of 09:53, 28 August 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit |
Latest revision as of 04:15, 26 October 2024 edit undo76.174.0.57 (talk) Fix. |
| (33 intermediate revisions by 21 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Unreferenced stub|auto=yes|date=December 2009}} |
|
|
|
{{cs1 config|name-list-style=vanc|display-authors=6}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| Watchedfields = changed |
|
| Watchedfields = changed |
|
| verifiedrevid = 437199958 |
|
| verifiedrevid = 447117038 |
|
| IUPAC_name = (''RS'')-''4-(aminomethyl)-1-benzylpyrrolidin-2-one'' |
|
| IUPAC_name = (''RS'')-4-(Aminomethyl)-1-benzylpyrrolidin-2-one |
|
| image = Nebracetam.svg |
|
| image = Nebracetam.svg |
|
| width = 150px |
|
| width = 150px |
|
| image2 = Nebracetam3d.png |
|
| image2 = Nebracetam3d.png |
|
| imagename = 1 : 1 mixture (racemate) |
|
| chirality = ] |
|
| drug_name = Nebracetam |
|
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
|
| legal_AU = S4 |
|
| legal_status = Unscheduled (US) |
|
|
|
| legal_US = unscheduled |
| ⚫ |
| routes_of_administration = Oral |
|
|
|
| legal_US_comment = Not FDA approved |
|
⚫ |
| routes_of_administration = |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
| Line 22: |
Line 25: |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 97205-34-0 |
|
| CAS_number = 97205-34-0 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| PubChem = 65926 |
|
| PubChem = 65926 |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEMBL = 2104682 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| Line 33: |
Line 39: |
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=12 | H=16 | N=2 | O=1 |
|
| C=12 | H=16 | N=2 | O=1 |
|
| molecular_weight = 204.268 g/mol |
|
|
| smiles = O=C2N(Cc1ccccc1)CC(C2)CN |
|
| smiles = O=C2N(Cc1ccccc1)CC(C2)CN |
|
| InChI = 1/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 |
|
|
| InChIKey = LCAFGJGYCUMTGS-UHFFFAOYAL |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 |
|
| StdInChI = 1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 |
| Line 43: |
Line 46: |
|
}} |
|
}} |
|
|
|
|
|
|
'''Nebracetam''' is an ] of the ] family that is a ] ] in rats.<ref>{{cite journal | vauthors = Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, Oshikawa S | title = Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats | journal = British Journal of Pharmacology | volume = 121 | issue = 3 | pages = 477–484 | date = June 1997 | pmid = 9179389 | pmc = 1564714 | doi = 10.1038/sj.bjp.0701161 }}</ref> Based on a human leukemic T cell experiment in 1991, it is believed to act as an ] for human ].<ref>{{cite journal | vauthors = Kitamura Y, Kaneda T, Nomura Y | title = Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist | journal = Japanese Journal of Pharmacology | volume = 55 | issue = 1 | pages = 177–180 | date = January 1991 | pmid = 2041225 | doi = 10.1254/jjp.55.177 | doi-access = free }}</ref> It is also believed to act as a ], like many other racetam drugs.<ref>{{cite journal | vauthors = Gabryel B, Pudełko A, Trzeciak HI, Cieślik P | title = Effect of nebracetam on content of high-energy phosphates and morphometry of rat astrocytes in vitro. Comparison with piracetam | journal = Acta Poloniae Pharmaceutica | volume = 57 | issue = 4 | pages = 289–298 | date = 2000 | pmid = 11126618 | url = https://pubmed.ncbi.nlm.nih.gov/11126618/ }}</ref> A ] method of synthesis was reported in 2008.<ref>{{Cite journal | vauthors = Yamashita S, Mase N, Takabe K |date=2008-09-22 |title=Chemoenzymatic total synthesis and determination of the absolute configuration of (S)-nebracetam |journal=Tetrahedron: Asymmetry |volume=19 |issue=18 |pages=2115–2118 |doi=10.1016/j.tetasy.2008.09.004 |issn=0957-4166}}</ref> {{As of|2023}}, human trials have not yet been conducted. |
|
'''Nebracetam''' is ] drug of the ] family, and an ] (] ]). |
|
|
|
|
|
|
==See also== |
|
== See also == |
|
* ] |
|
* ] |
|
* ] |
|
* ] |
|
* ] |
|
* ] |
|
|
|
|
|
== References == |
|
|
{{reflist|2}} |
|
|
|
|
|
{{Racetams}} |
|
{{Racetams}} |
|
|
{{Muscarinic acetylcholine receptor modulators}} |
|
|
|
|
| ⚫ |
] |
|
| ⚫ |
] |
|
|
] |
|
] |
|
⚫ |
] |
|
|
|
|
|
] |
|
⚫ |
] |
|
|
|
|
|
{{nervous-system-drug-stub}} |
|
{{nervous-system-drug-stub}} |